As a molecule with such a role, the development of inhibitors of FGL2 may help reverse immunosuppression in the tumor microenvironment and may play an essential role in targeting glioma-mediated immunosuppressive therapy. The gene discussed is FGL2; the disease is central nervous system cancer.